시장보고서
상품코드
1957959

바벤시오(아벨루맙) 시장 보고서(2026년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Bavencio (Avelumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 4,490 금액 안내 화살표 ₩ 6,770,000
PDF & Excel (Site License) help
PDF & Excel 보고서를 동일 기업의 동일 사업장 내의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 6,490 금액 안내 화살표 ₩ 9,786,000
PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 8,490 금액 안내 화살표 ₩ 12,802,000
카드담기
※ 부가세 별도
한글목차
영문목차

바벤시오(아벨루맙) 시장 규모는 최근 급성장하고 있습니다. 2025년 54만 달러에서 2026년에는 63만 달러에 이르고, CAGR 16.8%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 면역항암제의 임상적 성공, 메르켈세포암에 대한 승인, 암 면역치료에 대한 투자 증가, 생존율 개선, PD-L1 억제제에 대한 규제 당국의 지원 등이 주요 요인으로 꼽힙니다.

바벤시오(아벨루맙) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 117만 달러에 이르고, CAGR은 16.5%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 새로운 종양 적응증으로의 확대, 전 세계 면역요법 도입 증가, 종양학 임상시험 증가, 바이오마커에 기반한 치료법 선택 개선, 헬스케어 분야의 종양학 관련 지출 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 면역관문억제제 도입 확대, PD-L1 표적치료제 확대, 고형암에서 면역치료제 사용 증가, 화학요법 및 표적치료제와의 병용요법, 희귀암 적응증에 대한 관심 증가 등이 있습니다.

암 발병률 증가는 향후 바벤티오(아벨루맙) 시장의 성장을 견인할 것으로 예측됩니다. 암은 체내에서 비정상적인 세포가 통제할 수 없을 정도로 증식, 확산되는 질병군입니다. 암 발병률 증가는 건강에 해로운 생활습관(부적절한 식습관, 운동 부족 등), 환경오염 물질에 대한 노출 증가, 진단 및 검진 기술의 발전 등의 요인에 기인합니다. 바벤티오(성분명: 아벨루맙)는 면역관문억제제로 작용하여 체내 자연 면역반응을 강화함으로써 암 치료를 돕습니다. 이를 통해 면역세포가 암세포를 보다 효과적으로 인식하고 파괴할 수 있어 환자의 생존율과 삶의 질(QOL) 향상에 기여합니다. 예를 들어, 미국암협회(American Cancer Society)에 따르면, 2023년 1월 기준 미국 내 신규 암 발병 건수는 2023년 195만 8,310건에 달할 것이며, 암 관련 사망은 60만 9,820건에 달할 것으로 보고됐습니다. 따라서 암 발병률 증가가 바벤티오(아벨루맙) 시장의 성장을 견인하고 있습니다.

바벤시오(아벨루맙) 시장의 주요 동향으로는 기술 통합 강화와 시장 확대를 위한 전략적 제휴를 꼽을 수 있습니다. 전략적 제휴는 조직이 자원, 전문지식, 역량을 결집하여 공동의 목표를 달성하기 위한 협력 계약을 의미합니다. 예를 들어, 2025년 5월 Aulos Bioscience는 Merck KGaA와 임상시험 제휴를 맺고 인터루킨-2(IL-2) 치료제인 AU-007과 바벤티오(아벨루맙), 저용량 알데스로이킨의 병용요법을 평가하기 위한 공동연구를 시작했습니다. 공동연구를 시작하였습니다. 이번 2상 임상시험은 고형암 치료에서 이 병용요법의 가능성을 평가하는 것을 목적으로 하고 있습니다. 전임상시험에서 바벤시오의 항 PD-L1 작용기전과 AU-007의 면역증강 특성이 시너지 효과를 발휘하여 유망한 종양 박멸 가능성을 보여주었습니다.

자주 묻는 질문

  • 바벤시오(아벨루맙) 시장 규모는 어떻게 변화하고 있나요?
  • 바벤시오(아벨루맙) 시장의 성장 요인은 무엇인가요?
  • 바벤시오(아벨루맙) 시장의 주요 동향은 무엇인가요?
  • 바벤시오(아벨루맙) 시장의 성장에 영향을 미치는 암 발병률은 어떻게 되나요?
  • 바벤시오(아벨루맙)와 관련된 최근 임상시험은 어떤 내용인가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

LSH 26.04.02

Bavencio (avelumab) is a medication used in the treatment of certain cancers. It contains avelumab as the active ingredient, an immunotherapy agent that works by enabling the body's immune system to better recognize and attack cancer cells.

The main indications for Bavencio (avelumab) include Merkel cell carcinoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, and gastric cancer. Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that originates in Merkel cells located in the outermost layer of the skin, known as the epidermis. The medication is administered through routes such as intravenous and subcutaneous injection and is used by end users including hospitals, clinics, and cancer research institutes.

Tariffs have impacted the bavencio market by increasing costs for monoclonal antibody production inputs, formulation materials, and temperature-controlled logistics. These impacts are strongest in regions dependent on imported immunotherapies, including asia pacific and emerging markets. Hospital procurement and oncology clinic budgets face higher acquisition costs. On the positive side, tariffs are encouraging localized immunotherapy manufacturing investments. This strengthens regional supply security and supports long-term market expansion.

The bavencio (avelumab) market research report is one of a series of new reports from The Business Research Company that provides bavencio (avelumab) market statistics, including bavencio (avelumab) industry global market size, regional shares, competitors with a bavencio (avelumab) market share, detailed bavencio (avelumab) market segments, market trends and opportunities, and any further data you may need to thrive in the bavencio (avelumab) industry. This bavencio (avelumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bavencio (avelumab) market size has grown rapidly in recent years. It will grow from $0.54 million in 2025 to $0.63 million in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to clinical success of immuno-oncology drugs, approval in merkel cell carcinoma, rising cancer immunotherapy investment, improved survival outcomes, regulatory support for pd-l1 inhibitors.

The bavencio (avelumab) market size is expected to see rapid growth in the next few years. It will grow to $1.17 million in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to expansion into new tumor indications, increasing global immunotherapy adoption, growth in oncology clinical trials, improved biomarker driven treatment selection, rising healthcare oncology spending. Major trends in the forecast period include growing adoption of immune checkpoint inhibitors, expansion of pd-l1 targeted therapies, rising use of immunotherapy in solid tumors, combination use with chemotherapy and targeted drugs, increased focus on rare cancer indications.

The increasing prevalence of cancer is expected to drive the growth of the Bavencio (avelumab) market going forward. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer prevalence is attributed to factors such as unhealthy lifestyle choices, including poor diet and physical inactivity, greater exposure to environmental pollutants, and improvements in diagnostic and screening technologies. Bavencio (avelumab) supports cancer treatment by acting as an immune checkpoint inhibitor that enhances the body's natural immune response, enabling immune cells to better recognize and destroy cancer cells, while improving survival outcomes and quality of life for patients. For instance, in January 2023, according to the American Cancer Society, the number of new cancer cases in the United States reached 1,958,310 in 2023, with 609,820 cancer-related deaths reported. Therefore, the rising prevalence of cancer is driving the growth of the Bavencio (avelumab) market.

A key trend in the Bavencio (avelumab) market is the adoption of strategic partnerships to strengthen technology integration and expand market reach. Strategic partnerships involve collaborative agreements in which organizations pool resources, expertise, and capabilities to achieve shared objectives. For instance, in May 2025, Aulos Bioscience partnered with Merck KGaA in a clinical trial collaboration to evaluate a combination therapy of AU-007, an interleukin-2 (IL-2) therapeutic, with Bavencio (avelumab) and low-dose aldesleukin. The Phase 2 trial is designed to assess the potential of this combination in treating solid tumors. Bavencio's anti-PD-L1 mechanism, together with AU-007's immune-enhancing properties, has shown promising tumor-eradicating potential in preclinical studies.

In March 2023, Merck KGaA acquired exclusive worldwide rights to BAVENCIO (avelumab) from Pfizer Inc. for an undisclosed amount following the termination of their alliance agreement. This move aligns with Merck KGaA's strategy to strengthen its oncology portfolio and underscores its long-term commitment to BAVENCIO as an important treatment option for cancers such as metastatic Merkel cell carcinoma and advanced renal cell carcinoma. Pfizer Inc. is a US-based pharmaceutical manufacturing company involved in the production of BAVENCIO (avelumab).

Major companies operating in the bavencio (avelumab) market are Merck & Co. Inc., Pfizer Inc

North America was the largest region in the bavencio(avelumab) market in 2025. The regions covered in the bavencio (avelumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bavencio (avelumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The bavencio (avelumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bavencio (Avelumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses bavencio (avelumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bavencio (avelumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bavencio (avelumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Indication: Merkel Cell Carcinoma; Non Small Cell Lung Cancer (NSCLC); Urothelial Carcinoma; Gastric Cancer
  • 2) By Route of Administration: Intravenous; Subcutaneous
  • 3) By End User: Hospitals; Clinics; Cancer Research Institutes
  • Companies Mentioned: Merck & Co. Inc.; Pfizer Inc
  • Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Bavencio (Avelumab) Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Bavencio (Avelumab) Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Bavencio (Avelumab) Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Bavencio (Avelumab) Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Growing Adoption Of Immune Checkpoint Inhibitors
    • 4.2.2 Expansion Of PD-L1 Targeted Therapies
    • 4.2.3 Rising Use Of Immunotherapy In Solid Tumors
    • 4.2.4 Combination Use With Chemotherapy And Targeted Drugs
    • 4.2.5 Increased Focus On Rare Cancer Indications

5. Bavencio (Avelumab) Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Oncology Clinics
  • 5.3 Cancer Research Institutes
  • 5.4 Specialty Pharmacies
  • 5.5 Immunotherapy Centers

6. Bavencio (Avelumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Bavencio (Avelumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Bavencio (Avelumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Bavencio (Avelumab) Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Bavencio (Avelumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Bavencio (Avelumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Bavencio (Avelumab) Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Bavencio (Avelumab) Market Segmentation

  • 9.1. Global Bavencio (Avelumab) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Merkel Cell Carcinoma, Non Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Gastric Cancer
  • 9.2. Global Bavencio (Avelumab) Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Intravenous, Subcutaneous
  • 9.3. Global Bavencio (Avelumab) Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Clinics, Cancer Research Institutes

10. Bavencio (Avelumab) Market Regional And Country Analysis

  • 10.1. Global Bavencio (Avelumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Bavencio (Avelumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Bavencio (Avelumab) Market

  • 11.1. Asia-Pacific Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Bavencio (Avelumab) Market

  • 12.1. China Bavencio (Avelumab) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Bavencio (Avelumab) Market

  • 13.1. India Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Bavencio (Avelumab) Market

  • 14.1. Japan Bavencio (Avelumab) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Bavencio (Avelumab) Market

  • 15.1. Australia Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Bavencio (Avelumab) Market

  • 16.1. South Korea Bavencio (Avelumab) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 16.2. South Korea Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Bavencio (Avelumab) Market

  • 17.1. Western Europe Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. Western Europe Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Bavencio (Avelumab) Market

  • 18.1. UK Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Bavencio (Avelumab) Market

  • 19.1. Germany Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Bavencio (Avelumab) Market

  • 20.1. France Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Bavencio (Avelumab) Market

  • 21.1. Eastern Europe Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 21.2. Eastern Europe Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Bavencio (Avelumab) Market

  • 22.1. North America Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 22.2. North America Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Bavencio (Avelumab) Market

  • 23.1. USA Bavencio (Avelumab) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 23.2. USA Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Bavencio (Avelumab) Market

  • 24.1. Canada Bavencio (Avelumab) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 24.2. Canada Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Bavencio (Avelumab) Market

  • 25.1. South America Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 25.2. South America Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Bavencio (Avelumab) Market

  • 26.1. Middle East Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Middle East Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Bavencio (Avelumab) Market

  • 27.1. Africa Bavencio (Avelumab) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 27.2. Africa Bavencio (Avelumab) Market, Segmentation By Indication, Segmentation By Route of Administration, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Bavencio (Avelumab) Market Regulatory and Investment Landscape

29. Bavencio (Avelumab) Market Competitive Landscape And Company Profiles

  • 29.1. Bavencio (Avelumab) Market Competitive Landscape And Market Share 2024
    • 29.1.1. Top 10 Companies (Ranked by revenue/share)
  • 29.2. Bavencio (Avelumab) Market - Company Scoring Matrix
    • 29.2.1. Market Revenues
    • 29.2.2. Product Innovation Score
    • 29.2.3. Brand Recognition
  • 29.3. Bavencio (Avelumab) Market Company Profiles
    • 29.3.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 29.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30. Global Bavencio (Avelumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Bavencio (Avelumab) Market

32. Bavencio (Avelumab) Market High Potential Countries, Segments and Strategies

  • 32.1 Bavencio (Avelumab) Market In 2030 - Countries Offering Most New Opportunities
  • 32.2 Bavencio (Avelumab) Market In 2030 - Segments Offering Most New Opportunities
  • 32.3 Bavencio (Avelumab) Market In 2030 - Growth Strategies
    • 32.3.1 Market Trend Based Strategies
    • 32.3.2 Competitor Strategies

33. Appendix

  • 33.1. Abbreviations
  • 33.2. Currencies
  • 33.3. Historic And Forecast Inflation Rates
  • 33.4. Research Inquiries
  • 33.5. The Business Research Company
  • 33.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기